Core Viewpoint - Lu Kang Pharmaceutical (600789) has received a government subsidy of 14,360,000.00 yuan, which is expected to positively impact the company's profits for the fiscal year 2025 [1] Financial Performance - As of December 9, 2025, Lu Kang Pharmaceutical's stock closed at 9.52 yuan, down 1.45% from the previous trading day [1] - The stock opened at 9.67 yuan, reached a high of 9.74 yuan, and a low of 9.51 yuan, with a trading volume of 2.56 billion yuan and a turnover rate of 2.97% [1] - The latest total market capitalization of the company is 85.55 billion yuan [1] Government Subsidy - The government subsidy received by Lu Kang Pharmaceutical accounts for 3.52% of the company's audited net profit for the fiscal year 2024 [1] - The subsidy is categorized as an asset-related government grant, which is anticipated to have a positive effect on the company's profits for the fiscal year 2025 [1] - The final accounting treatment and impact on annual profit and loss will be confirmed by the auditing institution [1]

Core Viewpoint - The launch of the National Medical Insurance Administration's drug price registration system reflects a strong support for pharmaceutical innovation and aims to enhance the modernization of drug price governance in China [1] Group 1: Drug Price Registration System - The new system operates on the principles of "one location for acceptance, nationwide sharing, and global openness," providing drug price registration and inquiry services for domestic and foreign pharmaceutical companies [1] - This initiative is expected to facilitate the international expansion of Chinese innovative drugs and attract high-quality new drugs from abroad into the Chinese market [1] Group 2: Market Dynamics - The importance of China's large-scale market in the global pharmaceutical landscape is increasing, leading to higher demands for improving the drug price governance system [1] - The pharmaceutical industry is experiencing a structural recovery trend, with both supply and demand sides reaching a turning point [1] Group 3: Investment Opportunities - The Guotai Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily fluctuation of up to 20% [1] - This index focuses on innovative pharmaceutical sectors, selecting listed companies with high R&D investment and strong innovation capabilities, reflecting the overall performance of leading companies in the pharmaceutical industry with growth and technological attributes [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.47% on December 9, with the Shanghai Composite Index closing at 3909.52, down 0.37%, and the Shenzhen Component Index at 13277.36, down 0.39% [1] Stock Performance - The leading stock decline was observed in "退市苏吴," which fell by 67.74% to a closing price of 0.40, with a trading volume of 2.0568 million shares and a transaction value of 90.8383 million yuan [1] - Other notable declines included "康艺药业" down 7.85% to 10.80, "母南通的" down 7.67% to 7.82, and "广济药业" down 5.85% to 7.89 [1] Capital Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 6.92 billion yuan from institutional investors, while retail investors contributed a net inflow of 3.85 billion yuan [3] - Specific stocks like "恒瑞医药" had a net inflow of 1.37 billion yuan from institutional investors, while "退市苏吴" saw a net inflow of 383.935 million yuan [3]

张夏衡团队是杭高院化学与材料科学学院的研究团队，面向绿色药物合成方法和工艺开发、活性分子精 准修饰等生物医药前沿领域，在国际权威期刊Nature、Nature Chemistry、Nature Communications、 Science Advances等发表多篇重要学术论文，为活性分子的绿色、可持续高效合成和精准修饰提供了有 力支撑。其新成果在2025年10月发表于《Nature》，提出了一种安全、经济的芳香胺直接脱氨官能团化 方法，颠覆了传统高风险工艺，为传统上广泛使用却因易爆性和高风险而受限的芳基重氮化学提供了一 种安全、经济的新方案，有望在制药、染料、材料制造等多个重要领域获得广泛应用。 本次《研究院合作协议》的签署将充分发挥双方科技、人才、项目、成果、产业链资源等优势，探索科 研与产业交融发展模式，为公司培养更多高素质、高技能的应用型人才，解决公司在研发、生产过程中 遇到的问题，提高经济效益。本次合作有助于公司丰富产品品类、扩充产品储备梯队，实现降本增效， 提升产品竞争力；同时探索布局创新药、生物医药等前沿领域，拥抱人工智能技术在化学合成方面的落 地应用，优化公司业务结构，促进公司长远战略规划逐 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient Agomelatine, which is primarily used for treating adult depression [1] Group 1: Company Information - The company involved is Guoyao Modern (国药现代), with its wholly-owned subsidiary Jiangsu Weichida Pharmaceutical Co., Ltd. (国药江苏威奇达) receiving the approval [1] - Agomelatine acts on melatonin receptors MT1 and MT2 and antagonizes 5-HT2C, helping to restore disrupted biological rhythms and exerting antidepressant effects [1] Group 2: Product Information - The clinical application of Agomelatine is mainly for the treatment of adult depression [1]

人民财讯12月9日电，海翔药业（002099）12月9日公告，12月8日，公司与国科大杭州高等研究院(简 称"杭高院")签署了《共建先进合成技术产业研究院合作协议》，双方将共同组建先进合成技术产业研 究院。产业研究院的研发方向主要聚焦医药原料药、中间体、染料、新材料的开发与工业化等，合作总 金额5000万元。张夏衡团队是杭高院化学与材料科学学院的研究团队，其新成果在2025年10月发表于 《Nature》，提出了一种安全、经济的芳香胺直接脱氨官能团化方法，颠覆了传统高风险工艺，为传统 上广泛使用却因易爆性和高风险而受限的芳基重氮化学提供了一种安全、经济的新方案，有望在制药、 染料、材料制造等多个重要领域获得广泛应用。 ...

智通财经APP讯，海翔药业(002099.SZ)公告，公司与国科大杭州高等研究院(简称"杭高院")签署了《共 建先进合成技术产业研究院合作协议》，产业研究院的研发方向主要聚焦医药原料药、中间体、染料、 新材料的开发与工业化等，合作总金额5000万元。 ...

Core Viewpoint - Xintiandi (301277.SZ) has received approval from the National Medical Products Administration for the raw material drug Ferrous Fumarate, which is used for the prevention and treatment of iron deficiency anemia [1] Group 1 - The approval includes the issuance of the "Chemical Raw Material Drug Marketing Application Approval Notice" for Ferrous Fumarate [1] - Ferrous Fumarate is an iron supplement that improves hemoglobin synthesis and alleviates symptoms related to anemia [1]

人民财讯12月9日电，新天地（301277）12月9日公告，公司收到国家药品监督管理局核准签发的富马酸 亚铁原料药《化学原料药上市申请批准通知书》。富马酸亚铁是一种用于预防和治疗缺铁性贫血的铁 剂，通过补充铁元素改善血红蛋白合成，缓解贫血相关症状。 ...

与此同时，在由上海证券报·中国证券网主办的2025"上证鹰·金质量"评选活动中，雅本化学再获"科技创新奖"。该奖项聚焦企业在技术研发、产品创新及产 业升级方面的突出贡献，雅本化学凭借其在研发能力建设、工艺技术改进及绿色化学实践等领域的持续投入与突破，赢得了评委的一致认可。 近年来，雅本化学坚持"创新驱动+绿色可持续"双轮驱动赋能创新医药、创新农药双主业发展，持续加大研发投入，推动核心产品技术升级，同时积极构建 完善的ESG管理体系，提升企业综合竞争力。此次连获两项大奖，不仅是对公司过往成绩的肯定，更为其未来高质量发展注入强劲动力。 2025年12月，在资本市场持续强化高质量发展导向的背景下，雅本化学（300261）（300261.SZ）凭借其在科技创新与环境、社会及治理（ESG）领域的突 出表现，连续获得两项主流证券媒体权威奖项，进一步巩固其在行业中的领先地位。 在"第十九届上市公司价值评选"中，雅本化学荣获"上市公司ESG百强"奖项，公司董事长蔡彤先生亦被授予"中国上市公司年度ESG先锋人物"称号。该评选 由证券时报主办，旨在表彰在可持续发展、社会责任和公司治理方面表现卓越的上市公司。雅本化学此次获奖，充分 ...